CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 45,789 enrolled
Drug / intervention
Quadrivalent influenza modRNA vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05540522
NCT05540522Phase 3Completed
CompareCT.gov

A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER

Pfizer·interventional·Posted Sep 14, 2022·Updated May 8, 2025

In Brief

A Phase 3 clinical trial evaluating Quadrivalent influenza modRNA vaccine and Quadrivalent influenza vaccine for Influenza, Human. Completed, enrolled 45,789 participants across 321 sites in 6 countries.

Detailed Summary

This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Human
CountriesArgentina, Chile, New Zealand, Philippines, South Africa, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedSep 14, 2022
Enrollment StartSep 12, 2022
Primary CompletionMar 12, 2024
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 3.8 years ago

Interventions

Quadrivalent influenza modRNA vaccinebiological

Quadrivalent influenza modRNA vaccine (single dose)

Quadrivalent influenza vaccinebiological

Licensed quadrivalent influenza vaccine (single dose)